Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab and Darbepoetin Alfa in Lower-Risk MDS
NCT04798339Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2021
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in myelodysplastic syndrome (MDS), sponsored by Moffitt Cancer Center. Started Mar 2021; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04798339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798339.